BACKGROUND
Vaccination with rVSV-ZEBOV is highly effective against Ebola virus, but protection against Bundibugyo virus (BDBV) is unproven. We evaluated the relative population impact and dose efficiency of a partially cross-protective hypothetical vaccine under operationally realistic constraints during a BDBV outbrea...
Jason R. Andrews, P. Mbala, P. Mukadi et al.· Lancet. Infectious Diseases...· 0 citations
ABSTRACT Background Latent tuberculosis infection (LTBI) is more frequent among people living with human immunodeficiency virus (HIV) (PLHIV), in whom immunosuppression favors reactivation. However, data from sub‐Saharan Africa remain limited. This study aimed to determine the prevalence of LTBI and identify its associ...
J. Kadima, A. Nkodila, P. Lutumba et al.· Public Health Challenges· 0 citations
The 2026 outbreak of Ebola virus disease caused by Bundibugyo virus shows that scientific innovation alone is insufficient; its public health impact depends on integrated, species-inclusive systems capable of rapidly detecting, evaluating, and responding to outbreaks caused by any human-pathogenic Orthoebolavirus spp.
The emergence of mpox as a global public health concern demands accurate and efficient molecular diagnostic tools for surveillance and outbreak management. The single-plex mpox virus (MPXV)-specific assays targeting B7R and TNF receptor (G2R) genes are widely used for this purpose. However, single-target approaches a...
Carmen Koo, J. Griffiths, Eugene Tan et al.· Scientific Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
